Compare QUIK & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QUIK | MOLN |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.5M | 158.9M |
| IPO Year | 1997 | 2021 |
| Metric | QUIK | MOLN |
|---|---|---|
| Price | $9.43 | $4.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $11.00 | $8.38 |
| AVG Volume (30 Days) | ★ 206.0K | 4.1K |
| Earning Date | 03-03-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,112,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.38 | $318.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.26 | $3.36 |
| 52 Week High | $10.14 | $5.36 |
| Indicator | QUIK | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 51.34 |
| Support Level | $5.51 | $3.51 |
| Resistance Level | N/A | $5.33 |
| Average True Range (ATR) | 0.79 | 0.27 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 74.32 | 46.82 |
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.